Metastatic Castration-resistant Prostate Cancer Clinical Trials in Cleveland, Ohio

11 recruitingCleveland, Ohio

Showing 111 of 11 trials

Recruiting
Phase 3

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic Neoplasms
Merck Sharp & Dohme LLC1,314 enrolled329 locationsNCT06136650
Recruiting
Phase 1Phase 2

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Colorectal, CancerProstate CancerCancer+12 more
Parabilis Medicines, Inc.595 enrolled33 locationsNCT05919264
Recruiting
Phase 1

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Solid Tumor+7 more
Exelixis1,314 enrolled122 locationsNCT05176483
Recruiting
Phase 3

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

Metastatic Castration-resistant Prostate Cancer
Telix Pharmaceuticals (Innovations) Pty Limited520 enrolled31 locationsNCT06520345
Recruiting
Phase 1

Study With [225Ac]Ac-FL-020 in mCRPC Participants

Metastatic Castration-resistant Prostate Cancer
Full-Life Technologies UK Limited50 enrolled11 locationsNCT06492122
Recruiting
Phase 3

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

Metastatic Castration-resistant Prostate Cancer
AstraZeneca670 enrolled90 locationsNCT07611110
Recruiting
Phase 2

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Metastatic Castration-resistant Prostate Cancer
Kyntra Bio75 enrolled20 locationsNCT06842498
Recruiting
Phase 1

A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer
AstraZeneca136 enrolled16 locationsNCT06879041
Recruiting
Phase 3

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

Metastatic Castration-resistant Prostate Cancer
Amgen675 enrolled164 locationsNCT06691984
Recruiting
Phase 1Phase 2

Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

Metastatic Castration-resistant Prostate Cancer
Merck Sharp & Dohme LLC1,200 enrolled21 locationsNCT02861573
Recruiting
Phase 2

Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer

Metastatic Prostate CancerMetastatic Castration-resistant Prostate Cancer
Case Comprehensive Cancer Center44 enrolled1 locationNCT06738303